Una sesión concisa y dirigida por expertos sobre la hipertensión pulmonar del Grupo 2—diagnóstico, clasificación actualizada y estrategias de tratamiento—con un análisis de caso en vivo.
A concise, expert-led session in Spanish exploring Group 2 pulmonary hypertension—its diagnosis, updated classification, and treatment strategies—featuring a live case discussion.
Pulmonary arterial hypertension (PAH) is a progressive disease with significant morbidity and mortality. Due to nonspecific symptoms, diagnosis can be challenging and subject to substantial delays. Using data from Mayo Clinic′s electronic health records, we looked at causes of delayed diagnosis and whether earlier diagnosis means better outcomes.
Landmark trials of sotatercept in pulmonary arterial hypertension (PAH) excluded patients with significant cardiopulmonary comorbidities. To evaluate the real-world effectiveness and safety of sotatercept in patients with Group I PAH and cardiopulmonary comorbidities.
“Why is there more variation in the females? Could it be due to their estrous cycle?” This was the question my co-mentor, Dr. Irina Petrache, posed when I shared the first data I generated as a first-year research fellow. It was 2007, and was in the lab of cardiothoracic surgeon Dr. Dan Meldrum at Indiana University.
This study quantified prior authorization (PA)—insurance-required approval—burden for pediatric pulmonary hypertension (PH) at an accredited center. Among 53 patients, 72% of 283 prescriptions between 2021 and 2023 required PA, with non-FDA-approved medications showing highest volume.
We read with great interest the recent article on patient-specific hemodynamic modeling to estimate microvascular disease burden and predict response to pulmonary endarterectomy (PEA) in chronic thromboembolic pulmonary hypertension (CTEPH) [1]. The integration of multiscale structure-based modeling with routine clinical data addresses the key challenges of quantifying distal microvascular remodeling and anticipating heterogeneous hemodynamic responses after technically successful PEA.
In this Living Legends in PH session, Rubin Tuder reflects on a career that has shaped modern pulmonary hypertension research. He discusses key scientific advances, including the Sugen–hypoxia rat model, and shares personal insights on discovery, mentorship, and the evolution of the PH field, joined by Paul Hassoun and Jason Hong.
Assessing operability in late-presenting ventricular septal defects (VSD) with pulmonary arterial hypertension (PAH) is complex. Although a comprehensive assessment is often recommended, pulmonary vascular resistance index (PVRI) is the cornerstone of most decisions
In 1980, while working as a pediatric resident in the newborn intensive care unit of a University-affiliated hospital, I was called urgently to the delivery room. The attending obstetrician had delivered a full-term infant without complications just minutes before my arrival.
Transition from parenteral prostanoids to oral selexipag may be considered in select patients with pulmonary arterial hypertension (PAH) to reduce the therapeutic burden imposed on patients and caregivers, but its safety and efficacy remain uncertain.
